Odyssey Therapeutics, a clinical-stage biopharmaceutical company, has appointed H. Martin Seidel to its Scientific Advisory Board.
Martin is currently CEO of IFM Therapeutics, overseeing multiple discovery and development programmes.
Prior to IFM, Martin spent over a decade at Novartis Institutes for Biomedical Research in senior leadership roles, including Head of the Genomics Institute of the Novartis Research Foundation and Global Head of Business Development & Licensing, where he oversaw a broad range of scientific collaborations and strategic transactions while advancing discovery programs into clinical development.
Martin said: “Odyssey is working in an area of biology that is particularly ripe for drug discovery, and the breadth of scientific capabilities the team has assembled is unusual in today’s biotech landscape. Having worked previously with members of the Odyssey scientific leadership team, I have developed a strong appreciation for their scientific rigor and ambition. My work has long focused on applying cutting-edge science to drug discovery, and I look forward to contributing my experience across target selection and translation as Odyssey advances its programs toward the clinic.”
Gary Glick, Founder and CEO of Odyssey Therapeutics, said: “Martin’s perspective, shaped by decades of advancing programs across diverse scientific platforms, will be highly valuable as we continue to identify and advance targets toward the clinic. We are pleased to welcome him to the Scientific Advisory Board at this important stage for the company.”